Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.
Medical Research Council Unit, Fajara, The Gambia.
Muhammed O
MO
Afolabi
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Alfred B
AB
Tiono
Medical Research Council Unit, Fajara, The Gambia.
Uche J
UJ
Adetifa
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Jean Baptiste
JB
Yaro
Medical Research Council Unit, Fajara, The Gambia.
Abdoulie
A
Drammeh
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Issa
I
Nébié
The Jenner Institute Laboratories, University of Oxford, Oxford, UK.
Carly
C
Bliss
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Susanne H
SH
Hodgson
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Nicholas A
NA
Anagnostou
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Guillaume S
GS
Sanou
Medical Research Council Unit, Fajara, The Gambia.
Ya Jankey
YJ
Jagne
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Oumarou
O
Ouedraogo
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Casimir
C
Tamara
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Nicolas
N
Ouedraogo
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Mirielle
M
Ouedraogo
Medical Research Council Unit, Fajara, The Gambia.
Jainaba
J
Njie-Jobe
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Amidou
A
Diarra
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Christopher Ja
CJ
Duncan
Keires AG, Bäumleingasse, Basel, Switzerland.
Riccardo
R
Cortese
ReiThera, Rome, Italy.|CEINGE, Naples, Italy.|Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Alfredo
A
Nicosia
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Rachel
R
Roberts
European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Nicola K
NK
Viebig
European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Odile
O
Leroy
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Alison M
AM
Lawrie
Medical Research Council Unit, Fajara, The Gambia.|Current address: Department of Immunology, Monash University, Prahran, Melbourne, Australia.
Katie L
KL
Flanagan
Medical Research Council Unit, Fajara, The Gambia.
Beate
B
Kampman
Kenya Medical Research Institute, Centre for Geographical Medical Research (Coast), Kilifi, Kenya.
Philip
P
Bejon
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Egeruan B
EB
Imoukhuede
The Jenner Institute Laboratories, University of Oxford, Oxford, UK.
Katie J
KJ
Ewer
The Jenner Institute Laboratories, University of Oxford, Oxford, UK.|Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
Adrian Vs
AV
Hill
Medical Research Council Unit, Fajara, The Gambia.
Kalifa
K
Bojang
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Sodiomon B
SB
Sirima
D000261:Adenoviruses, Simian; D000354:Africa, Western / Q000453:epidemiology; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D058501:Enzyme-Linked Immunospot Assay; D000939:Epitopes / Q000276:immunology; D005714:Gambia; D005822:Genetic Vectors / Q000009:adverse effects; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D017063:Outcome Assessment, Health Care; D014616:Vaccinia virus
D000913:Antibodies, Protozoan; D000939:Epitopes; D017780:Malaria Vaccines